Brexpiprazole is an active pharmaceutical ingredient in the Other Antipsychotics group (N05AX). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
GBOfficial regulatory label· revised November 28, 2025[1]
RXULTI is indicated for the treatment of schizophrenia in adults and adolescents aged 13 years and older.
How to take
GB
CACanada· Health Canada
6 products
Uses
CAOfficial regulatory label· revised March 22, 2025[2]
4 Geriatrics 01/2024 TABLE OF CONTENTS Sections or subsections that are not applicable at the time of authorization are not listed. RECENT MAJOR LABEL CHANGES .........................................................................................
2 TABLE OF CONTENTS ............................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION ..................................................................
Showing 240 of 477. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
[1]MHRA (UK) · PLGB506970022 · revised November 28, 2025
[2]Health Canada (DPD) · 02461749 · revised March 22, 2025
[3]European Medicines Agency · EMEA/H/C/003841 · revised March 23, 2026
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.
Posology Adult population The recommended starting dose for brexpiprazole is 1 mg once daily on days 1 to 4. Based on the patient’s clinical response and tolerability, the brexpiprazole dose can be titrated to 2 mg once daily on day 5 through day 7 and then to 4 mg on day 8.
The recommended target dose range is 2 mg to 4 mg once daily. The maximum recommended daily dose is 4 mg. 5 mg once daily on days 1 to 4. The brexpiprazole dose should be titrated to 1 mg once daily on day 5 through day 7 and then to 2 mg on day 8.
Weekly dose increases can be made in 1 mg increments based on clinical response and tolerability. The recommended target dose range is 2 mg to 4 mg once daily. The maximum recommended daily dose is 4 mg. Switching from other antipsychotics to brexpiprazole When switching from other antipsychotics to brexpiprazole, gradual cross-titration should be considered, with gradual discontinuation of the previous treatment while brexpiprazole treatment is initiated.
Switching to other antipsychotics from brexpiprazole When switching to other antipsychotics from brexpiprazole, no gradual cross-titration is needed. The new antipsychotic should be initiated in its lowest dose while brexpiprazole is discontinued.
It should be considered that plasma concentration of brexpiprazole will decline gradually and will be completely washed out in 1 to 2 weeks. 2). It is not possible to advise on a minimum effective/safe dose in this population. 2). 2). CYP2D6 poor metabolisers Dosing modifications to half the recommended doses is required for patients with known CYP2D6 poor metaboliser status.
2). Dose adjustments due to interactions Dose adjustments should be made in patients taking concomitant strong CYP3A4 inhibitors/inducers or strong CYP2D6 inhibitors. 5). In case of adverse reactions despite dose adjustments of RXULTI, the necessity of concomitant use of RXULTI and CYP2D6 or CYP3A4 inhibitor should be reassessed.
, rifampicin), in a patient stabilised on brexpiprazole it is necessary to titrate the daily dose of brexpiprazole stepwise up to double the recommended dose over the course of 1 to 2 weeks. Thereafter, if according to the clinical response, further dose adjustments are required, the dose may be increased up to a maximum of three times the recommended daily dose.
Daily dose must not exceed 12 mg when brexpiprazole is used concomitantly with strong CYP3A4 inducers. 5). CYP3A4 inducers exert their effect in a time-dependent manner and may take at least 2 weeks to reach maximal effect after introduction.
Conversely, on discontinuation, CYP3A4 induction may take at least 2 weeks to decline. Paediatric population The safety and efficacy of brexpiprazole in children and adolescents aged less than 13 years have not been established. No data are available.
Method of administration Oral use. The film-coated tablets can be taken with or without food.
This is not medical advice. Consult a qualified healthcare professional.
Side effects & warnings
GBOfficial regulatory label· Adverse reactions· revised November 28, 2025[1]
6%). Tabulated list of adverse reactions The incidences of the ADRs associated with brexpiprazole therapy are tabulated below. The table is based on adverse reactions reported in short-term placebo-controlled phase 2 and 3 adult clinical trials with relevant therapeutic doses (2 mg to 4 mg) and short-term placebo- controlled phase 3 paediatric clinical trials with relevant therapeutic doses (1 mg to 4 mg).
All ADRs are listed by system organ class (SOC) and frequency: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1 000 to < 1/100), rare (≥ 1/10 000 to < 1/1 000), very rare (< 1/10 000) and not known (cannot be estimated from the available data).
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness. 6) SOC Very common Common Uncommon Not known Investigations Blood prolactin increased2 Blood creatine phosphokinase increased Blood pressure increased Blood triglycerides increased Hepatic enzymes increased 1 Includes also sedation and hypersomnia 2 The categorisation of blood prolactin increased is based on Potentially Clinically Relevant (PCR) criteria of > 1 × upper limit of normal (ULN).
2 % in placebo. 4 %). 4. Akathisia From fixed-dose trials there appears to be a dose-response relationship for akathisia in patients treated with brexpiprazole, with an increasing frequency with higher doses. 2 % of subjects in the placebo group.
7 %). 4 %, none-serious) in the placebo group. 6 %). Overall, in the brexpiprazole clinical development program for schizophrenia, one death due to suicide occurred but was not considered drug related by the investigator. Spontaneous cases reporting completed suicide and suicide attempt have been reported in the post-marketing setting.
4. 5 %) reported in subjects receiving placebo. The incidence of TEAEs in long-term trials was similar to that of the short-term trials. The effects of brexpiprazole at therapeutic (4 mg) and supra-therapeutic (12 mg) doses on QT interval were evaluated in subjects with schizophrenia or schizoaffective disorder in a randomised, double-blind, placebo- and positive-controlled (moxifloxacin), parallel-arm trial.
1). 8 % in the placebo group. 4 % of the subjects discontinued due to weight gain. 2 kg at week 52. 1 kg at week 52. 4. 5 % in the placebo group in short-term, controlled trials. 60 %) were observed in females compared to males in short-term trials.
1 […]
GBOfficial regulatory label· Warnings and precautions· revised November 28, 2025[1]
During antipsychotic treatment, improvement in the patient's clinical condition may take several days to some weeks. Patients should be closely monitored throughout this period. 8). Close supervision of high-risk patients should accompany antipsychotic treatment.
Cardiovascular disorders Brexpiprazole has not been evaluated in patients with a history of myocardial infarction/ischaemic heart disease or clinically significant cardiovascular disease since such patients were excluded from clinical trials.
Brexpiprazole should be used with caution in patients with known cardiovascular disease (history of myocardial infarction or ischaemic heart disease, heart failure, or conduction abnormalities), cerebrovascular disease, conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medicinal products) or hypertension (including accelerated or malignant).
QT prolongation QT prolongation can develop in patients treated with antipsychotics. In clinical trials, only a few, non-serious QT prolongations have been reported with brexpiprazole. 1). Venous thromboembolism Cases of venous thromboembolism (VTE) have been reported with antipsychotics.
Since patients treated with antipsychotics often present with acquired risk factors for VTE, all possible risk factors for VTE should be identified before and during treatment with brexpiprazole, and preventive measures should be undertaken.
Orthostatic hypotension and syncope Adverse reactions related to orthostatic hypotension can include dizziness, light-headedness and tachycardia. Generally, these risks are greatest at the beginning of treatment with antipsychotics and during dose escalation.
, heart failure, myocardial infarction, ischemia, or conduction abnormalities), history of cerebrovascular disease, as well as patients who are antipsychotic-naïve. 2). 8). Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac dysrhythmia).
Additional signs may include increased creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. If a patient develops signs and symptoms indicative of NMS or presents with unexplained high fever without additional clinical manifestations of NMS, brexpiprazole must be discontinued immediately.
This is not medical advice. Consult a qualified healthcare professional.
Who should not take it
GBOfficial regulatory label· Contraindications· revised November 28, 2025[1]
1.
This is not medical advice. Consult a qualified healthcare professional.
5 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ........................................................ 5 4 DOSAGE AND ADMINISTRATION .................................................................................. 1 Dosing Considerations ............................................................................................
CAOfficial regulatory label· revised March 22, 2025[2]
4 Geriatrics 01/2024 TABLE OF CONTENTS Sections or subsections that are not applicable at the time of authorization are not listed. RECENT MAJOR LABEL CHANGES .........................................................................................
2 TABLE OF CONTENTS ............................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION ..................................................................
This is not medical advice. Consult a qualified healthcare professional.
Side effects & warnings
CAOfficial regulatory label· Adverse reactions· revised March 22, 2025[2]
). REXULTI should only be prescribed in patients with MDD by clinicians who are aware of the importance and are experienced in the early detection and management of the safety issues associated with this class of drugs. The efficacy and safety of REXULTI in the adjunctive treatment of MDD were demonstrated in 6-week, double-blind, placebo-controlled trials in adult patients.
Therefore, the required length of adjunctive treatment with REXULTI is not known. 2 Recommended Dose and Dosage Adjustment, Adjunctive Treatment in Major Depressive Disorder (MDD)). Clinical trials evaluating REXULTI in MDD did not include REXULTI monotherapy treatment arms.
It is, therefore, not known whether efficacy in adjunct treatment is due to REXULTI alone or from combined treatment with an antidepressant. REXULTI is not indicated as an as needed (prn) treatment for AAD. 1 Clinical Trials by Indication, Agitation Associated with Alzheimer’s Dementia (AAD)).
The efficacy and safety of REXULTI in the treatment of AAD were demonstrated in two 12-week, randomized, double-blind, placebo-controlled, fixed-dose trials in adult patients. 4 Geriatrics) and the risk predictors for stroke or existing cardiovascular comorbidities.
1 Pediatrics Pediatrics (< 18 years of age): The safety and efficacy of REXULTI have not been established in patients less than 18 years of age. 3 Pediatrics). 2 Geriatrics Geriatrics (> 65 years of age): The safety and efficacy of REXULTI have not been systematically evaluated in schizophrenia or MDD patients 65 years of age or older, or in AAD patients 90 years of age or older.
4 Geriatrics and 10 CLINICAL PHARMACOLOGY). 2 CONTRAINDICATIONS REXULTI is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container.
For a complete listing, see 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING. 5 Post-Market Adverse Reactions). 1 Dosing Considerations • REXULTI is taken orally, once daily with or without food (see 10 CLINICAL PHARMACOLOGY). • Dosage increases are based on clinical response and tolerability.
• Dosage should be maintained at the lowest effective level and patients should be periodically reassessed to determine continued need and appropriate dosage for treatment. • Patients should have baseline and periodic monitoring of blood glucose, fasting lipid profile and body weight.
• It is recommended that patients have their complete blood count (CBC), white blood cell (WBC) and differential counts prior to starting REXULTI and then periodically throughout treatment as neutropenia, granulocytopenia and agranulocytosis have been reported during antipsychotic use.
Serious Warnings and Precautions WARNING:
INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA Increased Mortality in Elderly Patients with Dementia Elderly patients with dementia treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo.
6-fold increase in the death rate in the drug-treated patients. 4 Geriatrics). 5 mg/day 2 mg/day 3 mg/day Schizophrenia The recommended starting dosage for REXULTI is 1 mg once daily on Days 1 to 4. The recommended target REXULTI dosage is 2 mg to 4 mg once daily.
In short-term fixed-dose clinical trials, the dose was titrated to 2 mg once daily on Day 5 through Day 7, then to 4 mg on Day 8. The maximum recommended daily dosage is 4 mg. Patients should be treated with the lowest effective dose that provides optimal clinical response and tolerability.
Adjunctive Treatment in Major Depressive Disorder (MDD) The dose range of 1 to 3 mg/day was evaluated as adjunctive treatment in clinical trials. 1 Clinical Trials by Indication, Adjunctive Treatment in Major Depressive Disorder (MDD)).
The required length of adjunctive treatment with REXULTI is not known. 1 Clinical Trials by Indication, Adjunctive Treatment in Major Depressive Disorder (MDD)). The […]
CAOfficial regulatory label· Warnings and precautions· revised March 22, 2025[2]
4 Geriatrics 01/2024 TABLE OF CONTENTS Sections or subsections that are not applicable at the time of authorization are not listed. RECENT MAJOR LABEL CHANGES .........................................................................................
2 TABLE OF CONTENTS ............................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION ..................................................................
8 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING ......................... 9 7 WARNINGS AND PRECAUTIONS .................................................................................. 9 General ...........................................................................................................................
This is not medical advice. Consult a qualified healthcare professional.
Who should not take it
CAOfficial regulatory label· Contraindications· revised March 22, 2025[2]
REXULTI is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing, see 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING.
5 Post-Market Adverse Reactions).
This is not medical advice. Consult a qualified healthcare professional.
Posology Adult population The recommended starting dose for brexpiprazole is 1 mg once daily on days 1 to 4. Based on the patient’s clinical response and tolerability, the brexpiprazole dose can be titrated to 2 mg once daily on day 5 through day 7 and then to 4 mg on day 8.
The recommended target dose range is 2 mg to 4 mg once daily. The maximum recommended daily dose is 4 mg. 5 mg once daily on days 1 to 4. The brexpiprazole dose should be titrated to 1 mg once daily on day 5 through day 7 and then to 2 mg on day 8.
Weekly dose increases can be made in 1 mg increments based on clinical response and tolerability. The recommended target dose range is 2 mg to 4 mg once daily. The maximum recommended daily dose is 4 mg. 4 Switching from other antipsychotics to brexpiprazole When switching from other antipsychotics to brexpiprazole, gradual cross-titration should be considered, with gradual discontinuation of the previous treatment while brexpiprazole treatment is initiated.
Switching to other antipsychotics from brexpiprazole When switching to other antipsychotics from brexpiprazole, no gradual cross-titration is needed. The new antipsychotic should be initiated in its lowest dose while brexpiprazole is discontinued.
It should be considered that plasma concentration of brexpiprazole will decline gradually and will be completely washed out in 1 to 2 weeks. 2). It is not possible to advise on a minimum effective/safe dose in this population. 2). 2). CYP2D6 poor metabolisers Dosing modifications to half the recommended doses is required for patients with known CYP2D6 poor metaboliser status.
2). Dose adjustments due to interactions Dose adjustments should be made in patients taking concomitant strong CYP3A4 inhibitors/inducers or strong CYP2D6 inhibitors. 5). In case of adverse reactions despite dose adjustments of RXULTI, the necessity of concomitant use of RXULTI and CYP2D6 or CYP3A4 inhibitor should be reassessed.
, rifampicin), in a patient stabilised on brexpiprazole it is necessary to titrate the daily dose of brexpiprazole stepwise up to 5 double the recommended dose over the course of 1 to 2 weeks. Thereafter, if according to the clinical response, further dose adjustments are required, the dose may be increased up to a maximum of three times the recommended daily dose.
Daily dose must not exceed 12 mg when brexpiprazole is used concomitantly with strong CYP3A4 inducers. 5). CYP3A4 inducers exert their effect in a time-dependent manner and may take at least 2 weeks to reach maximal effect after introduction.
Conversely, on discontinuation, CYP3A4 induction may take at least 2 weeks to decline. Paediatric population The safety and efficacy of brexpiprazole in children and adolescents aged less than 13 years have not been established. No data are available.
Method of administration Oral use. The film-coated tablets can be taken with or without food.
This is not medical advice. Consult a qualified healthcare professional.
Side effects & warnings
EUOfficial regulatory label· Adverse reactions· revised March 23, 2026[3]
6%). Tabulated list of adverse reactions The incidences of the ADRs associated with brexpiprazole therapy are tabulated below. The table is based on adverse reactions reported in short--term placebo--controlled phase 2 and 3 adult clinical trials with relevant therapeutic doses (2 mg to 4 mg) and short-term placebo-controlled phase 3 paediatric clinical trials with relevant therapeutic doses (1 mg to 4 mg).
All ADRs are listed by system organ class (SOC) and frequency: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1 000 to < 1/100), rare (≥ 1/10 000 to < 1/1 000), very rare (< 1/10 000) and not known (cannot be estimated from the available data).
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness. 6) 11 SOC Very common Common Uncommon Not known Investigations Blood prolactin increased2 Blood creatine phosphokinase increased Blood pressure increased Blood triglycerides increased Hepatic enzymes increased 1 Includes also sedation and hypersomnia 2The categorisation of blood prolactin increased is based on Potentially Clinically Relevant (PCR) criteria of > 1 × upper limit of normal (ULN).
2 % in placebo. 4 %). 4. Akathisia From fixed -dose trials there appears to be a dose-response relationship for akathisia in patients treated with brexpiprazole, with an increasing frequency with higher doses. 2 % of subjects in the placebo group.
7 %). 4 %, none-serious) in the placebo group. 6 %). Overall, in the brexpiprazole clinical development program for schizophrenia, one death due to suicide occurred but was not considered drug related by the investigator. Spontaneous cases reporting completed suicide and suicide attempt have been reported in the post-marketing setting.
4. 5 %) reported in subjects receiving placebo. The incidence of TEAEs in long-term trials was similar to that of the short-term trials. The effects of brexpiprazole at therapeutic (4 mg) and supra-therapeutic (12 mg) doses on QT interval were evaluated in subjects with schizophrenia or schizoaffective disorder in a randomised, double- blind, placebo- and positive-controlled (moxifloxacin), parallel-arm trial.
1). 8 % in the placebo group. 4 % of the subjects discontinued due to weight gain. 2 kg at week 52. 1 kg at week 52. 4. 5 % in the placebo group in short-term, controlled trials. 60 %) were observed in females compared to males in short-term trials.
4 % in the placebo […]
EUOfficial regulatory label· Warnings and precautions· revised March 23, 2026[3]
During antipsychotic treatment, improvement in the patient’s clinical condition may take several days to some weeks. Patients should be closely monitored throughout this period. 8). Close supervision of high-risk patients should accompany antipsychotic treatment.
Cardiovascular disorders Brexpiprazole has not been evaluated in patients with a history of myocardial infarction/ischaemic heart disease or clinically significant cardiovascular disease since such patients were excluded from clinical trials.
Brexpiprazole should be used with caution in patients with known cardiovascular disease (history of myocardial infarction or ischaemic heart disease, heart failure, or conduction abnormalities), cerebrovascular disease, conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medicinal products) or hypertension (including accelerated or malignant).
QT prolongation QT prolongation can develop in patients treated with antipsychotics. In clinical trials, only a few, non- serious QT prolongations have been reported with brexpiprazole. 1). Venous thromboembolism Cases of venous thromboembolism (VTE) have been reported with antipsychotics.
Since patients treated with antipsychotics often present with acquired risk factors for VTE, all possible risk factors for VTE should be identified before and during treatment with brexpiprazole, and preventive measures should be undertaken.
6 Orthostatic hypotension and syncope Adverse reactions related to orthostatic hypotension can include dizziness, light-headedness and tachycardia. Generally, these risks are greatest at the beginning of treatment with antipsychotics and during dose escalation.
, heart failure, myocardial infarction, ischemia, or conduction abnormalities), history of cerebrovascular disease, as well as patients who are antipsychotic-naïve. 2). 8). Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac dysrhythmia).
Additional signs may include increased creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. If a patient develops signs and symptoms indicative of NMS or presents with unexplained high fever without additional clinical manifestations of NMS, brexpiprazole must be discontinued immediately.
This is not medical advice. Consult a qualified healthcare professional.
Who should not take it
EUOfficial regulatory label· Contraindications· revised March 23, 2026[3]
1.
This is not medical advice. Consult a qualified healthcare professional.
Extrapyramidal symptoms (EPS) Extrapyramidal symptoms (including acute dystonia) are known class effects for antipsychotics. Brexpiprazole should be used with caution in patients with a known history of EPS. Tardive dyskinesia A syndrome of potentially irreversible, involuntary, dyskinetic movements may develop in patients treated with antipsychotics.
Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to rely upon prevalence estimates to predict, at the inception of antipsychotic treatment, which patients are likely to develop the syndrome.
If signs and symptoms of tardive dyskinesia appear in a patient on brexpiprazole, dose reduction or discontinuation should be considered. These symptoms can temporally deteriorate or can even arise after discontinuation of treatment.
Cerebrovascular adverse reactions In placebo-controlled trials with some antipsychotics in elderly patients with dementia, there was a higher incidence of cerebrovascular adverse reactions (cerebrovascular accidents and transient ischemic attacks), including fatalities, compared to placebo-treated subjects.
Elderly patients with dementia-related psychosis Brexpiprazole has not been studied in elderly patients with dementia and is not recommended for the treatment of elderly patients with dementia due to increased risk of overall mortality.
Hyperglycaemia and diabetes mellitus Hyperglycaemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics. Risk factors that may predispose patients to severe complications include obesity and family history of diabetes.
Patients treated with any antipsychotics, including brexpiprazole, should be observed for signs and symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia and weakness). Fasting plasma glucose should be assessed before or soon after the initiation of the antipsychotic treatment.
During long term treatment the plasma glucose levels should be monitored regularly for worsening of glucose control. Weight gain and dyslipidaemia Antipsychotics including brexpiprazole have been associated with metabolic changes, including weight gain and dyslipidaemia.
An increased frequency of weight gain has been observed with increased duration of […]
Extrapyramidal symptoms (EPS) Extrapyramidal symptoms (including acute dystonia) are known class effects for antipsychotics. Brexpiprazole should be used with caution in patients with a known history of EPS. Tardive dyskinesia A syndrome of potentially irreversible, involuntary, dyskinetic movements may develop in patients treated with antipsychotics.
Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to rely upon prevalence estimates to predict, at the inception of antipsychotic treatment, which patients are likely to develop the syndrome.
If signs and symptoms of tardive dyskinesia appear in a patient on brexpiprazole, dose reduction or discontinuation should be considered. These symptoms can temporally deteriorate or can even arise after discontinuation of treatment.
Cerebrovascular adverse reactions In placebo-controlled trials with some antipsychotics in elderly patients with dementia, there was a higher incidence of cerebrovascular adverse reactions (cerebrovascular accidents and transient ischemic attacks), including fatalities, compared to placebo-treated subjects.
Elderly patients with dementia-related psychosis Brexpiprazole has not been studied in elderly patients with dementia and is not recommended for the treatment of elderly patients with dementia due to increased risk of overall mortality.
Hyperglycaemia and diabetes mellitus Hyperglycaemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics. Risk factors that may predispose patients to severe complications include obesity and family history of diabetes.
Patients treated with any antipsychotics, including brexpiprazole, should be observed for signs and symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia and weakness). Fasting plasma glucose should be assessed before or soon after the initiation of the antipsychotic treatment.
During long term treatment the plasma glucose levels should be monitored regularly for worsening of glucose control. Weight gain and dyslipidaemia Antipsychotics including brexpiprazole have been associated with metabolic changes, including weight gain and dyslipidaemia.
An increased frequency of weight gain has been observed with increased duration of […]